CompumedicsASX:CMP -4.00%62 EV-to-EBITDA is 10.83 as of Jul. 03, 2026, which is 31% below its 10-year median of 15.74. GuruFocus rates ASX:CMP with a GF Score™ of 62/100 and a GF Value™ of A$0.32 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 513 Medical Devices & Instruments companies, Compumedics ranks better than 61.99% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Compumedics's enterprise value is A$59.34 Mil.
Compumedics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.48 Mil. Therefore, Compumedics's EV-to-EBITDA for today is 10.83.
The historical rank and industry rank for Compumedics's EV-to-EBITDA or its related term are showing as below:
ASX:CMP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.22 Med: 15.74 Max: 42.08
Current: 10.83
During the past 13 years, the highest EV-to-EBITDA of Compumedics was 42.08. The lowest was -18.22. And the median was 15.74.
ASX:CMP's EV-to-EBITDA is ranked better than 61.99% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.33
vs ASX:CMP: 10.83
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Compumedics (ASX:CMP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Compumedics's PE Ratio (TTM) for today is calculated as:
Compumedics's share price for today is A$0.24.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Compumedics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Compumedics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Compumedics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Compumedics's EV-to-EBITDA falls into.
Compumedics's current Enterprise Value is A$59.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Compumedics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compumedics (ASX:CMP) has a EV-to-EBITDA of 10.83 as of Jul. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Compumedics. This is 31% below median its historical median of 15.74. According to the industry distribution chart, Compumedics ranks #195 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 38%.
Is Compumedics' EV-to-EBITDA too high?
Compumedics' current EV-to-EBITDA of 10.83 is 31% below median its 10-year median of 15.74. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.33. Compumedics' value of 10.83 is 24.4% below this industry median. Based on the distribution chart, Compumedics ranks #195 out of 513 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Compumedics has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #195 out of 513 companies for EV-to-EBITDA. This puts Compumedics in the upper half of its industry. The industry median EV-to-EBITDA is 14.33. Compumedics' value of 10.83 is 24.4% below this benchmark. While the company's 10-year median is 15.74 vs. the industry median of 14.33, Compumedics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.33, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current EV-to-EBITDA of 10.83 is 24.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Compumedics. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current EV-to-EBITDA is 10.83, which is 31% below median its own 10-year median of 15.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.32, compared to a current price of A$0.24 — trading 25% below its estimated fair value. The current EV-to-EBITDA is 10.83, which is 31% below median its 10-year median of 15.74 and 24.4% below the Medical Devices & Instruments industry median of 14.33. Compumedics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current EV-to-EBITDA is 10.83 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.24 is trading 25% below its estimated GF Value™ of A$0.32.
GuruFocus considers Compumedics to be Modestly Undervalued.
Key valuation signals for ASX:CMP:
EV-to-EBITDA: 10.83 (31% below median its 10-year median of 15.74)
GF Value™: A$0.32 vs. price of A$0.24 (25% below fair value)
Industry Position: 24.4% below the Medical Devices & Instruments median (#195 of 513)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
62GF Score
Get the complete analysis for ASX:CMP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
